No Data
Sales growth of core varieties: REMEGEN's revenue in 2024 is expected to increase by more than 50% year-on-year, but it has not yet achieved profitability.
① The company has increased its R&D investment, while sales revenue of Tai Tasi Pu and Vidi Situt Monoclonal Antibody has grown rapidly, with the product gross margin continuing to rise and the sales expense ratio significantly decreasing. Therefore, it is expected that the company will report a net loss in 2024, showing a trend of reduced losses; ② The company's Phase III clinical trial for IgAN of Tai Tasi Pu in China has concluded, and data readout is expected in the first half of 2025.
The sales growth of the Paigebin product drives performance increase, with Xiamen Amoytop Biotech achieving a new high in net profit in Q4.
① With the continuous upgrade of hepatitis B chronic prevention and treatment guidelines and the ongoing accumulation of clinical cure scientific evidence, cognitive awareness will be promoted, and the number of patients accepting treatment will show an upward trend; ② Interferon has common side effects such as flu-like symptoms, and relatively, patients have a greater workload in treatment and management, which may affect the treatment choices between doctors and patients.
Demand in the AI vision sector is strong. ArcSoft Corporation expects revenue and net profit in Q4 2024 to reach the highest level in nearly three years for a single quarter.
ArcSoft Corporation expects to achieve revenue of 0.241 billion yuan in the fourth quarter of 2024, with a forecasted net income attributable to the parent company of 89.71 million yuan. Both performance indicators set a new quarterly high for the company since early 2021; As a provider of Machine Vision algorithm services and solutions, ArcSoft Corporation benefits from the strong demand for AI technology across various industries, particularly in the fields of Consumer Electronics and Smart Automobile.
The Fourth Global Autonomous Driving Summit opened today, accelerating the implementation of high-level autonomous driving.
On January 14, the Fourth Global Autonomous Driving Summit will officially commence at the Beijing Centergate Technologies National Independent Innovation Demonstration Zone Exhibition Trade Center - Conference Center. Li Liang from Guoxin Securities stated that with the continuous release of several mandatory and recommended national standards in the Asia Vets connected vehicle sector, the commercialization of high-level autonomous driving will accelerate.
Two companies have new developments: Changchun Up Optotech and Lingyun Guang's subsidiary Changguang Chenxin's IPO has been terminated. Sizhirui has updated the submission of financial materials | Star IPO Weekly Report.
① Changchun Up Optotech and Lingyun Optical are both publicly listed companies that hold more than 5% of the shares in Changguang Chinchip, with Changchun Up Optotech holding a share of 25.56%; Lingyun Optical holds 10.22%. ② The domestic surgical robot manufacturer Siasun Robot&Automation is a company that is listed under the fifth set of standards on the Star, with its core product being the "Kangduo" surgical endoscopic robot.
Xindong Lianke: The automotive-grade six-axis chip is planned to ship by mid-year; low-altitude economy and humanoid robots are the future incremental markets | Direct coverage of the Shareholder meeting.
① To meet the customer demand in the Autos market, the company is currently developing products that can apply to automotive-grade six-axis chip products. These are expected to enter the market within one to two years during the normal research and development process; ② From the perspective of Institutions, the core performance Indicators of the company's high-performance gyroscope have already reached internationally advanced levels. Due to the lack of competitors of the same level in the domestic market, the company possesses bargaining power, and the gross margin remains at a high level.